Also listed on Askgene Pharma Inc., an earlier holder on the record. The recorded assignments below show how it moved.

Term ends no later than Mar 30, 2040 · Medium confidence

Computed 20-year base term

In force on USPTO's status record and by its fee record. A terminal disclaimer on file may shorten this term, possibly to a date already past; its reference document is unresolved, so the date above is an upper bound and no earlier date is guessed.

Held by Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Filed Jul 18, 2019 as application 16/516,223 · Granted Nov 22, 2022

Base term plus 256 days of patent term adjustment (USPTO delay)

Today

20 years from filing

Ends no later than Mar 30, 2040

2019 2040

Clock starts
Jul 18, 2019

Ends no later than
Mar 30, 2040

Granted
Nov 22, 2022

base term patent term adjustment fee events Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

256

Days of term adjustment

Read from the USPTO patent term adjustment record, not recalculated here.

Unresolved

Terminal disclaimer

On file, reference document not resolved, so the date above is an upper bound. We do not guess the cap.

1 of 3

Maintenance fees paid

Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.

Family applications on record here

Applications sharing this one's continuity chain whose file history this site holds. The family may have others.

This patent's term runs 256 days past its 20-year base term on prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. 1 of 3 maintenance fees is paid so far. Confidence: Medium. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.

Step	Input	Date after this step	Confidence
Base term, 20 years from filing	Clock starts Jul 18, 2019, when this application, 16/516,223, was filed	Jul 18, 2039	High confidence
Continuity chain	Every parent in the chain resolved	no change	High confidence
Patent term adjustment	+256 days, USPTO patent term adjustment record	Mar 30, 2040	High confidence
Terminal disclaimer cap	Disclaimer on file (approved), reference document not resolved	no cap applied, and none guessed	Medium confidence
Patent term extension	None on file	no change	High confidence
Fee events	1 of 3 maintenance fees paid	In force	High confidence
Computed term end	The steps above, in order	no later than Mar 30, 2040	Medium confidence

This family

US 11,505,618	this patent no later than Mar 2040	no later than Mar 2040
US 12,312,413	In force no later than Jul 2039	no later than Jul 2039

The applications whose file history this site holds. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.

Recorded	Assignor	Assignee	Conveyance
Mar 16, 2022 Reel 59287, frame 95	Lu, Yuefeng; Shanebeck, Kurt; Li, Lu; Zhang, Shiwen; Yang, Lan; Lu, Jian-feng; Liu, Lei	Askgene Pharma, Inc.; Jiangsu Aosaikang Pharmaceutical Co., Ltd.	Assignment of Assignor's Interest
Mar 16, 2022 Reel 59287, frame 145	Jiangsu Aosaikang Pharmaceutical Co., Ltd.	Askgene Pharma Inc.	Assignment of Assignor's Interest
Mar 16, 2022 reel/frame not recorded	Li, Lu; Liu, Lei; Lu, Jian-feng; Lu, Yuefeng; Shanebeck, Kurt; Yang, Lan; Zhang, Shiwen	Askgene Pharma, Inc.	Assignment of Assignor's Interest
Mar 16, 2022 reel/frame not recorded	Li, Lu; Liu, Lei; Lu, Jian-feng; Lu, Yuefeng; Shanebeck, Kurt; Yang, Lan; Zhang, Shiwen	Jiangsu Aosaikang Pharmaceutical Co., Ltd.	Assignment of Assignor's Interest
Oct 22, 2026 Reel 76471, frame 538	Askgene Pharma, Inc.	Jiangsu Aosaikang Pharmaceutical Co., Ltd.	Assignment of Assignor's Interest

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

What's changing

Mar 2040

Term ends no later than Mar 30, 2040. Maintenance fees still fall due before then

Note

A terminal disclaimer is on file and its reference is not resolved. No cap is applied and none is guessed

Note

The 256 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us

Open question

A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than Mar 30, 2040. We will not guess the cap.

Citations

later US patents cite this one

That is above the median of utility patents granted in 2022 in our data, the only group it is compared against. How we rank

Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built

This computed term ends no later than the date shown; an unresolved terminal disclaimer may end it earlier. Related patents and pending applications may cover overlapping subject matter.

In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.

Novel Antibodies and Methods for Making and Using the Same